AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Altasciences Wins Most Successful Early Phase Research (Preclinical & Phase I) at the 2019 CARE Awards

May 8, 2019

LAVAL, Québec--(BUSINESS WIRE)--May 8, 2019--Altasciences won in the Most Successful Early Phase Research (Preclinical & Phase I) category at the 2019 Clinical and Research Excellence (CARE) Awards. The award win was announced during a ceremony presented by Ben Nemzer at the Hyatt Regency Boston, US on May 2, 2019.

Now in its fourth year, the CARE Awards drew a crowd of pharmaceutical and biomedtech industry leaders and innovators from companies both large and small, who gathered to celebrate the achievements of those working to advance the quality of healthcare worldwide by bringing new and needed medicines to market. Categories for the awards spanned the full spectrum of the drug development process, and the winners of these prestigious trophies were as diverse as the categories themselves.

Altasciences undertook an innovative approach to identify and recruit asymptomatic patients with nonalcoholic steatohepatitis or NASH, a disease for which recruitment competition is quite high. This project required creative and insightful thinking, analysis and preparation to proactively build a patient database for a condition that is asymptomatic, for which affected patients lack awareness and hence motivation to participate in a clinical trial. The upfront investment of effort paid off. Despite joining the trial 2 months behind other sites, Altasciences became the top enrolling site, recruiting more than 35% of the overall patients.

I am proud of our team’s unwavering commitment and passion to bringing better and more cost effective drugs to the people who need them, faster. This recognition by the industry of our ability to provide innovative solutions and of our effective participant recruitment and retention strategies reflects Altasciences’ ongoing drive to meet and exceed sponsor expectations, ” stated Chris Perkin, CEO, at Altasciences.

To see the full list of CARE Awards winners please visit :https://pharmaintelligence.informa.com/events/awards/care-awards-2019

About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies of all sizes a proven, flexible approach to preclinical and early phase clinical studies, from lead candidate selection to proof of concept. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

About Informa Pharma Intelligence
Trusted by over 3,000 of the world’s leading pharmaceutical companies, CROs, med and biotech organizations, and healthcare service providers, the Pharma Intelligence suite of intelligence solutions delivers vital, accurate, and timely intelligence about the drug development pipeline to pharmaceutical and biomedical decision makers around the world. At Pharma Intelligence, global teams of subject area experts follow and analyze key diseases, clinical trials, drug approvals and R&D activities as part of the breadth and depth of data available to customers.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190508005815/en/

CONTACT: Julie-Ann Cabana

Altasciences

913 304-4505

jcabana@altasciences.com

KEYWORD: NORTH AMERICA CANADA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL PROFESSIONAL SERVICES CONSULTING

SOURCE: Altasciences

Copyright Business Wire 2019.

PUB: 05/08/2019 03:10 PM/DISC: 05/08/2019 03:10 PM

http://www.businesswire.com/news/home/20190508005815/en